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Figure 1: Bone densities (percentage relative to baseline 
QCT) of the lesions over time, average ± SD; (A) SF vs. MF RT; 
(B) each lesion type. Symbols indicate significant differences 
within lesions (*blastic, † mixed), or between lesion types at 
ten weeks (**). 
 
Conclusion: In general, 10 weeks after RT in patients with 
femoral metastases a significant increase in bone density was 
seen in blastic and mixed lesions, but not in lytic lesions. 
However, the subsequent effect of these changes on femoral 
bone strength remains unknown. Since higher total doses did 
not lead to significantly higher bone densities, the clinical 
relevance of MF over SF for stabilizing femoral bone with 
metastases can be questioned. 
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Purpose or Objective: Advanced primary and recurrent 
rectal cancers (RC) may cause significant pelvic morbidity 
including pain, dysfunction and hematochezia. Palliative 
pelvic radiotherapy (PPRT) is often used but symptomatic 
effects and toxicities are poorly documented and optimal 
treatment schedules remain undefined. Aims of this 
prospective multicenter phase-II study were to evaluate 
changes in symptom severity and explore quality of life (QOL) 
and toxicity after PPRT of RC using a common palliative 
radiotherapy regimen. 
 
Material and Methods: Patients with symptomatic pelvic RC 
(primary or recurrent) prescribed PPRT with 30-39 Gy in 3 Gy 
fractions were eligible. Treatment volume included primary 
tumor or recurrence and enlarged pelvic lymph nodes, if 
indicated. Subjects identified a target symptom (TS) as their 
principal pelvic complaint requiring palliation. Primary 
outcome was self-reported TS severity relative to baseline 12 
weeks after PPRT. Pelvic symptom burden including toxicity 
and QOL (EORTC QLQ C30) were assessed before, at the end 
of, and six and 12 weeks after PPRT. 
 
Results: From Q4/2009-Q3/2015, 51 patients were included 
at 8/9 Norwegian radiotherapy centers. Thirty-three patients 
were evaluable 12 weeks after PPRT, and 16 (31%) did not 
complete the study due to progressive cancer (n=6) and 
death (n=10). Albumin < 36 g/L (OR=1.31 (95% CI 1.11-1.54)) 
and age ≤ 79 yrs (OR=4.79 (95% CI 0.97 -23.65)) were 
independent predictors of study drop-out. Median delivered 
dose was 36 Gy (6–39). Pain (n=24), rectal dysfunction (n=16), 
and hematochezia (n=9) were the most common TS. 28/33 
(85%) evaluable patients reported that their TS had either 
resolved or improved 12 weeks after PPRT. 4/33 (12%) 
reported unchanged TS severity, while one patient had 
worsening TS severity at the 12-week follow-up. Forty-two of 
the 51 included patients (82%) reported complete resolution 
or improvement of the TS at at least one of the three follow-
up visits. Hematochezia responded most rapidly and 
consistently with all evaluable patients reporting 
improvement or resolution. The time course of pain and 
rectal dysfunction severity was variable. Twelve weeks after 
PPRT, 10/13 (77%) and 9/10 (90%) of evaluable patients who 
had identified TS pain and rectal dysfunction, respectively, 
reported improvement or resolution. Non-target pelvic 
symptom severity decreased during the study. Median global 
QOL scores remained stable at follow-up visits. There was no 
grade 4 toxicity reported. Median survival after PPRT was 9 
months (0-51). 
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Conclusion: In the majority of patients with symptomatic 
primary or recurrent RC, PPRT with 30-39 Gy contributes to 
relief of pain, rectal dysfunction, hematochezia, and other 
pelvic symptoms, with little toxicity. A large proportion of 
patients prescribed PPRT of RC have very limited life 
expectancy and future studies should investigate patient 
selection and further simplification of PPRT. 
 
Poster: Clinical track: Elderly  
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Purpose or Objective: In this study, we investigated the 
disease distribution and analyzed treatment compliance for 
the elderly patients received radiation therapy (RT). 
 
Material and Methods: Among the patients underwent RT 
from January 2005 to May 2014 in this hospital, the 670 
patients aged over 75 were retrospectively analyzed in this 
study. We classified the patients for each disease and 
analyzed the RT compliance for each disease. The RT 
compliance was determined whether or not the scheduled RT 
plan was completed. The Chi-squared test and multiple 
logistic regression analysis were used for the factors (region, 
economic status, age, gender, disease type, treatment aim, 
ECOG score) influencing the RT compliance. 
 
Results: The mean age of the patients was 78 years (range; 
75~99 years). The disease distribution was as follows; Lung 
cancer in 127 patients (19.0%), metastasis in 123 patients 
(18.4%), gastrointestinal (GI) cancer in 116 patients (17.3%), 
gynecologic cancer in 110 patients(16.4%), head and neck 
cancer in 53 patients (7.9%), genitourinary cancer in 44 
patients (6.6%), breast cancer in 30 patients (4.5%), 
hematologic cancer in 22 patients (3.3%), skin cancer in 17 
patients (2.5%), brain tumor in 9 patients (1.3%), and others 
in 19 patients (2.8%). The RT compliance in total 670 patients 
was 82.6% The 116 patients of all patients could not 
complete their course of scheduled treatment. According to 
χ2 test analysis, the factors found to be related to the RT 
compliance were; gender(p=0.001), disease type(p=0.014), 
and patient`s ECOG score(p<0.001). Multiple logistic analysis 
showed that gender(p=0.016) and patient`s ECOG 
score(p<0.001) were related to RT compliance. 
 
Conclusion: Based on these preliminary results, more than 
80% of elderly patients received RT for lung cancer, 
metastatic cancer, GI cancer, gynecologic cancer, head and 
neck cancer, and genitourinary cancer. This study showed 
that the most significant factor related to RT compliance was 
the patient’s functional status. Further comparative studies 
with younger patients are also needed. 
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Purpose or Objective: To evaluate the effect of shortening 
overall treatment time by hypofractionated radiotherapy for 
cT1-T2N0M0 glottic carcinomas. Results for local control, 
survival and toxicity were calculated and compared to cT1-
